Elsevier Science, Inc.

SHERPA: Unknown

People

  1. Scher
    Scher
  2. Motzer
    Motzer
  3. Bajorin
    Bajorin
  4. Morris
    Morris
  5. Reuter
    Reuter
  6. Rosenberg
    Rosenberg
  7. Sheinfeld
    Sheinfeld
  8. Feldman
    Feldman
  9. Russo
    Russo
  10. Solit
    Solit

Groups

  1. Department of Medicine (389)
  2. Genitourinary Oncology Service (389)
  3. Solid Tumor Oncology Division (389)
  4. Surgery (113)
  5. Urology (109)
  6. Department of Pathology and Laboratory Medicine (65)
  7. Survivorship Research (59)
  8. GSK Faculty (58)
  9. Epidemiology and Biostatistics (51)
  10. Human Oncology and Pathogenesis Program (41)
Search Within
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (318)
  2. Meeting Abstract (26)
  3. Review (14)
  4. Correspondence (12)
  5. Editorial (10)
  6. Conference Paper (4)
  7. Research Letter (3)
  8. Guidelines (2)
Groups
  1. Department of Medicine (389)
  2. Genitourinary Oncology Service (389)
  3. Solid Tumor Oncology Division (389)
  4. Surgery (113)
  5. Urology (109)
  6. Department of Pathology and Laboratory Medicine (65)

More Groups

People
  1. Howard Scher (119)
  2. Robert Motzer (111)
  3. Dean Bajorin (58)
  4. Michael Morris (39)
  5. Jonathan Rosenberg (35)
  6. Victor Reuter (35)

More People

Years
  1. 2025 (8)
  2. 2024 (21)
  3. 2023 (28)
  4. 2022 (18)
  5. 2021 (20)
  6. 2020 (23)

More Years

Publications
  1. European Urology (118)
  2. Journal of Urology (101)
  3. Lancet Oncology (52)
  4. Urology (52)
  5. Lancet (14)
  6. Value in Health (12)

More Publications

Results (389)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): A randomised, double-blind phase 3 trial
    Journal Article

    Araujo, J. C.; Trudel, G. C.; Saad, F.; Armstrong, A. J.; Yu, E. Y.; Bellmunt, J.; Wilding, G.; McCaffrey, J.; Serrano, S. V.; Matveev, V. B.; more...
    Lancet Oncology (2013)

    Fulltext@MSK | Save
  • Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial
    Journal Article

    Stein, A.; Bellmunt, J.; Escudier, B.; Kim, D.; Stergiopoulos, S. G.; Mietlowski, W.; Motzer, R. J.
    European Urology (2013)

    Fulltext@MSK | Save
  • Management of biochemical recurrence after primary treatment of prostate cancer: A systematic review of the literature
    Journal Article

    Punnen, S.; Cooperberg, M. R.; D'Amico, A. V.; Karakiewicz, P. I.; Moul, J. W.; Scher, H. I.; Schlomm, T.; Freedland, S. J.
    European Urology (2013)

    Fulltext@MSK | Save
  • Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: Patient-reported outcome results of a randomised phase 3 trial
    Journal Article

    Basch, E.; Autio, K.; Ryan, C. J.; Mulders, P.; Shore, N.; Kheoh, T.; Fizazi, K.; Logothetis, C. J.; Rathkopf, D.; Smith, M. R.; more...
    Lancet Oncology (2013)

    Fulltext@MSK | Save
  • Mutational analysis of circulating tumor cells using a novel microfluidic collection device and qPCR assay
    Journal Article

    Harb, W.; Fan, A.; Tran, T.; Danila, D. C.; Keys, D.; Schwartz, M.; Ionescu-Zanetti, C.
    Translational Oncology (2013)

    Fulltext@MSK | Save
  • Noninvasive phosphorus magnetic resonance spectroscopic imaging predicts outcome to first-line chemotherapy in newly diagnosed patients with diffuse large B-cell lymphoma
    Journal Article

    Arias-Mendoza, F.; Payne, G. S.; Zakian, K.; Stubbs, M.; O'Connor, O. A.; Mojahed, H.; Smith, M. R.; Schwarz, A. J.; Shukla-Dave, A.; Howe, F.; more...
    Academic Radiology (2013)

    Fulltext@MSK | Save
  • Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A systematic review and meta-analysis of randomized clinical trials
    Journal Article

    Sonpavde, G.; Je, Y.; Schutz, F.; Galsky, M. D.; Paluri, R.; Rosenberg, J. E.; Bellmunt, J.; Choueiri, T. K.
    Critical Reviews in Oncology/Hematology (2013)

    Fulltext@MSK | Save
  • Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: Overall survival analysis and updated results from a randomised phase 3 trial
    Journal Article

    Motzer, R. J.; Escudier, B.; Tomczak, P.; Hutson, T. E.; Michaelson, M. D.; Negrier, S.; Oudard, S.; Gore, M. E.; Tarazi, J.; Hariharan, S.; more...
    Lancet Oncology (2013)

    Fulltext@MSK | Save
  • Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma
    Journal Article

    Hakimi, A. A.; Chen, Y. B.; Wren, J.; Gonen, M.; Abdel-Wahab, O.; Heguy, A.; Liu, H.; Takeda, S.; Tickoo, S. K.; Reuter, V. E.; more...
    European Urology (2013)

    Fulltext@MSK | Save
  • Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: A retrospective analysis of pooled, prospective phase 2 trials
    Journal Article

    Sonpavde, G.; Pond, G. R.; Fougeray, R.; Choueiri, T. K.; Qu, A. Q.; Vaughn, D. J.; Niegisch, G.; Albers, P.; James, N. D.; Wong, Y. N.; more...
    European Urology (2013)

    Fulltext@MSK | Save